TAK-700 (Orteronel) (BioDeep_00001875326)

   


代谢物信息卡片


6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide

化学式: C18H17N3O2 (307.1320702)
中文名称: 6-(6,7-二氢-7-羟基-5H-吡咯并[1,2-c]咪唑-7-基)-n-甲基-2-萘羧酰胺
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O
InChI: InChI=1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22)

描述信息

同义名列表

2 个代谢物同义名

6-(7-Hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl)-N-methyl-2-naphthamide; TAK-700 (Orteronel)



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Murtuza Rampurwala, Kari B Wisinski, Mark E Burkard, Sima Ehsani, Ruth M O'Regan, Lakeesha Carmichael, KyungMann Kim, Jill Kolesar, Amye J Tevaarwerk. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Investigational new drugs. 2017 02; 35(1):87-94. doi: 10.1007/s10637-016-0403-2. [PMID: 27826831]
  • Ajit Suri, Sandeepraj Pusalkar, Yuexian Li, Shimoga Prakash. Absorption, Distribution, and Excretion of the Investigational Agent Orteronel (TAK-700) in Healthy Male Subjects: A Phase 1, Open-Label, Single-Dose Study. Clinical pharmacology in drug development. 2016 May; 5(3):180-7. doi: 10.1002/cpdd.234. [PMID: 27163496]
  • Ajit Suri, Theresa Pham, David B MacLean. A Phase 1, Randomized, Single-Dose Crossover Pharmacokinetic Study to Investigate the Effect of Food Intake on Absorption of Orteronel (TAK-700) in Healthy Male Subjects. Clinical pharmacology in drug development. 2016 May; 5(3):188-95. doi: 10.1002/cpdd.233. [PMID: 27163497]
  • A Goto, Y Moriya, T Takeuchi, T Mandai, Y Tagawa, T Kondo, S Asahi. Pharmacokinetics and Urinary Excretion Mechanism of Orteronel (TAK-700), A Novel 17,20-Lyase Inhibitor, in Animals. Drug research. 2016 Apr; 66(4):217-22. doi: 10.1055/s-0035-1564118. [PMID: 26418412]
  • Mohd Zainuddin, A B Vinod, Sandip Dhondiram Gurav, Anitha Police, Avinash Kumar, Chandan Mithra, Purushottam Dewang, Raghava Reddy Kethiri, Ramesh Mullangi. Preclinical assessment of Orteronel(®), a CYP17A1 enzyme inhibitor in rats. European journal of drug metabolism and pharmacokinetics. 2016 Feb; 41(1):1-7. doi: 10.1007/s13318-014-0229-2. [PMID: 25297456]
  • A Suri, S Chapel, C Lu, K Venkatakrishnan. Physiologically based and population PK modeling in optimizing drug development: A predict-learn-confirm analysis. Clinical pharmacology and therapeutics. 2015 Sep; 98(3):336-44. doi: 10.1002/cpt.155. [PMID: 26031410]
  • Daniel P Petrylak, Jitendra G Gandhi, William R Clark, Elisabeth Heath, Jianqing Lin, William K Oh, David B Agus, Bradley Carthon, Susan Moran, Ning Kong, Ajit Suri, Michael Bargfrede, Glenn Liu. Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. Investigational new drugs. 2015 Apr; 33(2):397-408. doi: 10.1007/s10637-014-0199-x. [PMID: 25556680]
  • Kazuhiro Suzuki, Seiichiro Ozono, Akito Yamaguchi, Hidekazu Koike, Hiroshi Matsui, Masao Nagata, Takatoshi Takubo, Kana Miyashita, Takafumi Matsushima, Hideyuki Akaza. A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer. Cancer chemotherapy and pharmacology. 2015 Feb; 75(2):373-80. doi: 10.1007/s00280-014-2654-y. [PMID: 25537627]
  • Chuang Lu, Ajit Suri, Wen Chyi Shyu, Shimoga Prakash. Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation. Biopharmaceutics & drug disposition. 2014 Dec; 35(9):543-52. doi: 10.1002/bdd.1919. [PMID: 25264242]
  • Eva Gupta, Troy Guthrie, Winston Tan. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). BMC urology. 2014 Jul; 14(?):55. doi: 10.1186/1471-2490-14-55. [PMID: 25062956]
  • Avinash Kumar, Vijay Kumar S, Sandip Gurav, Mohd Zainuddin, Purushottam Dewang, Raghava Reddy Kethiri, Sriram Rajagopal, Ramesh Mullangi. Development and validation of an RP-HPLC method for the quantitation of Orteronel (TAK-700), a CYP17A1 enzyme inhibitor, in rat plasma and its application to a pharmacokinetic study. Biomedical chromatography : BMC. 2013 Dec; 27(12):1590-4. doi: 10.1002/bmc.2964. [PMID: 23788266]
  • Masuo Yamaoka, Takahito Hara, Hideo Araki, Tomohiro Kaku, Takenori Hitaka, Akihiro Tasaka, Masami Kusaka. Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys. The Journal of steroid biochemistry and molecular biology. 2013 Nov; 138(?):298-306. doi: 10.1016/j.jsbmb.2013.07.002. [PMID: 23856460]
  • Takahito Hara, Jin Kouno, Tomohiro Kaku, Toshiyuki Takeuchi, Masami Kusaka, Akihiro Tasaka, Masuo Yamaoka. Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. The Journal of steroid biochemistry and molecular biology. 2013 Mar; 134(?):80-91. doi: 10.1016/j.jsbmb.2012.10.020. [PMID: 23146910]
  • Sandip Gurav, Anitha Police, Mohd Zainuddin, Ravindra Ramachandra Punde, Purushottam Dewang, V Chandregowda, Raghava Reddy Kethiri, Sriram Rajagopal, Ramesh Mullangi. Development and validation of an enantioselective LC-MS/MS method to quantify enantiomers of (±)-TAK-700 in rat plasma: lack of in vivo inversion of (+)-TAK-700 (Orteronel) to its antipode. Biomedical chromatography : BMC. 2013 Feb; 27(2):164-71. doi: 10.1002/bmc.2764. [PMID: 22714983]
  • Sandip Gurav, Anitha Police, Mohd Zainuddin, Junaid Hassan Farooqui, Krishna Reddy G, Raghava Reddy Kethiri, Sriram Rajagopal, Ramesh Mullangi. Development and validation of a highly sensitive LC-ESI-MS/MS method for the determination of Orteronel® (TAK-700) in rat plasma: application to a pharmacokinetic study. Bioanalysis. 2012 Jun; 4(12):1471-80. doi: 10.4155/bio.12.107. [PMID: 22793031]
  • Masuo Yamaoka, Takahito Hara, Takenori Hitaka, Tomohiro Kaku, Toshiyuki Takeuchi, Junzo Takahashi, Satoru Asahi, Hiroshi Miki, Akihiro Tasaka, Masami Kusaka. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. The Journal of steroid biochemistry and molecular biology. 2012 Apr; 129(3-5):115-28. doi: 10.1016/j.jsbmb.2012.01.001. [PMID: 22249003]